{"entity":{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","aka":[],"tldr":"Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs.","summary":"Robert Doebele was first author of the 2020 Lancet Oncology integrated analysis of the entrectinib trials in NTRK fusion-positive solid tumours, part of the evidence for the drug's tumour-agnostic approval. As a physician-scientist at the University of Colorado he described resistance mechanisms in ROS1- and NTRK-driven lung cancers and helped establish patient-derived models of oncogene-addicted cancers.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy"],"related":[],"cancers":["ntrk-fusion-nsclc","ros1-positive-nsclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-doebele-entrectinib-ntrk-lancet-oncol-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic oncologist and drug developer","specialisms":["NTRK fusions","ROS1-positive lung cancer","Acquired resistance to kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doebele%5BAuthor%5D"}],"papers":[]},"route":"/people/robert-doebele/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"paper":[{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/"}]}}